Curon Biopharmaceutical Overview

  • Founded
  • 2018
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $150M
Latest Deal Amount
  • Investors
  • 3

Curon Biopharmaceutical General Information

Description

Developer of drugs intended designed for immuno-oncology therapies. The company's drugs consist of multiple class-leading cancer immunotherapeutic agents in the world that could address the shortcomings of current cancer treatment paradigm, enabling a physician to provide advanced cancer immunotherapies to their patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Primary Office
  • Shanghai
  • China
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Curon Biopharmaceutical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 30-Jul-2018 $150M 00000 Completed Pre-Clinical Trials
To view Curon Biopharmaceutical’s complete valuation and funding history, request access »

Curon Biopharmaceutical Executive Team (1)

Name Title Board Seat Contact Info
Paul Song Chief Scientific Officer
To view Curon Biopharmaceutical’s complete executive team members history, request access »

Curon Biopharmaceutical Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
6 Dimensions Capital Venture Capital Minority 000 0000 000000 0
Boyu Capital PE/Buyout Minority 000 0000 000000 0
Temasek Holdings Sovereign Wealth Fund Minority 000 0000 000000 0
To view Curon Biopharmaceutical’s complete investors history, request access »